Table S5: Unsolicited AEs through 28 Days of the Final Vaccination by MedDRA SOC, PT, and Maximum Reported Severity

|  | Placebo (N=12) n (%) | | | | | | | 20 µg (N=18) n (%) | | | | | | | 100 µg (N=18) n (%) | | | | | | | Overall (N=48) n (%) |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| MedDRA SOC/PT | Any | Gr 1 | | Gr 2 | | Gr 3 | | Any | | Gr 1 | | Gr 2 | | Gr 3 | Any | Gr 1 | | Gr 2 | | Gr 3 | | Any |
| Any AE | 11 (91.7) | 7 (58.3) | | 3 (25.0) | | 1 (8.3) | | 15 (83.3) | | 9 (50.0) | | 4 (22.2) | | 2 (11.1) | 10 (55.6) | 6 (33.3) | | 4 (22.2) | | 0 (0.0) | | 36 (75.0) |
| Infections and infestations | 6 (50.0) | 4 (33.3) | | 1 (8.3) | | 1 (8.3) | | 9 (50.0) | | 6 (33.3) | | 2 (11.1) | | 1 (5.6) | 4 (22.2) | 2 (11.1) | | 2 (11.1) | | 0 (0.0) | | 19 (39.6) |
| Upper respiratory tract infection | 6 (50.0) | 4 (33.3) | | 1 (8.3) | | 1 (8.3) | | 5 (27.8) | | 3 (16.7) | | 1 (5.6) | | 1 (5.6) | 3 (16.7) | 2 (11.1) | | 1 (5.6) | | 0 (0.0) | | 14 (29.2) |
| Rhinitis | 0 (0.0) | 0 (0.0) | | 0 (0.0) | | 0 (0.0) | | 1 (5.6) | | 1 (5.6) | | 0 (0.0) | | 0 (0.0) | 0 (0.0) | 0 (0.0) | | 0 (0.0) | | 0 (0.0) | | 1 (2.1) |
| Conjunctivitis | 1 (8.3) | 1 (8.3) | | 0 (0.0) | | 0 (0.0) | | 0 (0.0) | | 0 (0.0) | | 0 (0.0) | | 0 (0.0) | 0 (0.0) | 0 (0.0) | | 0 (0.0) | | 0 (0.0) | | 1 (2.1) |
| Cystitis | 0 (0.0) | 0 (0.0) | | 0 (0.0) | | 0 (0.0) | | 1 (5.6) | | 0 (0.0) | | 1 (5.6) | | 0 (0.0) | 0 (0.0) | 0 (0.0) | | 0 (0.0) | | 0 (0.0) | | 1 (2.1) |
| Hordeolum | 0 (0.0) | 0 (0.0) | | 0 (0.0) | | 0 (0.0) | | 1 (5.6) | | 1 (5.6) | | 0 (0.0) | | 0 (0.0) | 0 (0.0) | 0 (0.0) | | 0 (0.0) | | 0 (0.0) | | 1 (2.1) |
| Lyme disease | 0 (0.0) | 0 (0.0) | | 0 (0.0) | | 0 (0.0) | | 0 (0.0) | | 0 (0.0) | | 0 (0.0) | | 0 (0.0) | 1 (5.6) | 0 (0.0) | | 1 (5.6) | | 0 (0.0) | | 1 (2.1) |
| Viral infection | 0 (0.0) | 0 (0.0) | | 0 (0.0) | | 0 (0.0) | | 1 (5.6) | | 1 (5.6) | | 0 (0.0) | | 0 (0.0) | 0 (0.0) | 0 (0.0) | | 0 (0.0) | | 0 (0.0) | | 1 (2.1) |
| Gastrointestinal disorders | 3 (25.0) | 2 (16.7) | | 1 (8.3) | | 0 (0.0) | | 5 (27.8) | | 5 (27.8) | | 0 (0.0) | | 0 (0.0) | 3 (16.7) | 3 (16.7) | | 0 (0.0) | | 0 (0.0) | | 11 (22.9) |
| Paraesthesia oral | 3 (25.0) | 3 (25.0) | | 0 (0.0) | | 0 (0.0) | | 3 (16.7) | | 3 (16.7) | | 0 (0.0) | | 0 (0.0) | 3 (16.7) | 3 (16.7) | | 0 (0.0) | | 0 (0.0) | | 9 (18.8) |
| Diarrhoea | 0 (0.0) | 0 (0.0) | | 0 (0.0) | | 0 (0.0) | | 1 (5.6) | | 1 (5.6) | | 0 (0.0) | | 0 (0.0) | 0 (0.0) | 0 (0.0) | | 0 (0.0) | | 0 (0.0) | | 1 (2.1) |
| Dyspepsia | 0 (0.0) | 0 (0.0) | | 0 (0.0) | | 0 (0.0) | | 1 (5.6) | | 1 (5.6) | | 0 (0.0) | | 0 (0.0) | 0 (0.0) | 0 (0.0) | | 0 (0.0) | | 0 (0.0) | | 1 (2.1) |
| Gastrooesophageal  reflux disease | 1 (8.3) | 0 (0.0) | | 1 (8.3) | | 0 (0.0) | | 0 (0.0) | | 0 (0.0) | | 0 (0.0) | | 0 (0.0) | 0 (0.0) | 0 (0.0) | | 0 (0.0) | | 0 (0.0) | | 1 (2.1) |
| Nervous system disorders | 2 (16.7) | 2 (16.7) | | 0 (0.0) | | 0 (0.0) | | 4 (22.2) | | 3 (16.7) | | 1 (5.6) | | 0 (0.0) | 2 (11.1) | 1 (5.6) | | 1 (5.6) | | 0 (0.0) | | 8 (16.7) |
| Headache | 2 (16.7) | 2 (16.7) | | 0 (0.0) | | 0 (0.0) | | 1 (5.6) | | 0 (0.0) | | 1 (5.6) | | 0 (0.0) | 0 (0.0) | 0 (0.0) | | 0 (0.0) | | 0 (0.0) | | 3 (6.3) |
| Dizziness | 0 (0.0) | 0 (0.0) | | 0 (0.0) | | 0 (0.0) | | 0 (0.0) | | 0 (0.0) | | 0 (0.0) | | 0 (0.0) | 1 (5.6) | 1 (5.6) | | 0 (0.0) | | 0 (0.0) | | 1 (2.1) |
| Hypoaesthesia | 1 (8.3) | 1 (8.3) | | 0 (0.0) | | 0 (0.0) | | 1 (5.6) | | 1 (5.6) | | 0 (0.0) | | 0 (0.0) | 0 (0.0) | 0 (0.0) | | 0 (0.0) | | 0 (0.0) | | 2 (4.2) |
| Presyncope | 0 (0.0) | | 0 (0.0) | | 0 (0.0) | | 0 (0.0) | | 1 (5.6) | | 1 (5.6) | | 0 (0.0) | 0 (0.0) | 1 (5.6) | 1 (5.6) | 0 (0.0) | | 0 (0.0) | | 2 (4.2) | |
| Disturbance in attention | 0 (0.0) | | 0 (0.0) | | 0 (0.0) | | 0 (0.0) | | 1 (5.6) | | 1 (5.6) | | 0 (0.0) | 0 (0.0) | 0 (0.0) | 0 (0.0) | 0 (0.0) | | 0 (0.0) | | 1 (2.1) | |
| Tension headache | 0 (0.0) | | 0 (0.0) | | 0 (0.0) | | 0 (0.0) | | 0 (0.0) | | 0 (0.0) | | 0 (0.0) | 0 (0.0) | 1 (5.6) | 0 (0.0) | 1 (5.6) | | 0 (0.0) | | 1 (2.1) | |
| Musculoskeletal and connective tissue disorders | 4 (33.3) | | 3 (25.0) | | 1 (8.3) | | 0 (0.0) | | 1 (5.6) | | 0 (0.0) | | 0 (0.0) | 1 (5.6) | 2 (11.1) | 1 (5.6) | 1 (5.6) | | 0 (0.0) | | 7 (14.6) | |
| Musculoskeletal chest pain | 0 (0.0) | | 0 (0.0) | | 0 (0.0) | | 0 (0.0) | | 1 (5.6) | | 1 (5.6) | | 0 (0.0) | 0 (0.0) | 0 (0.0) | 0 (0.0) | 0 (0.0) | | 0 (0.0) | | 1 (2.1) | |
| Musculoskeletal pain | 0 (0.0) | 0 (0.0) | | 0 (0.0) | | 0 (0.0) | | 1 (5.6) | | 0 (0.0) | | 0 (0.0) | | 1 (5.6) | 0 (0.0) | 0 (0.0) | | 0 (0.0) | | 0 (0.0) | | 1 (2.1) |
| Plantar fasciitis | 0 (0.0) | 0 (0.0) | | 0 (0.0) | | 0 (0.0) | | 0 (0.0) | | 0 (0.0) | | 0 (0.0) | | 0 (0.0) | 1 (5.6) | 0 (0.0) | | 1 (5.6) | | 0 (0.0) | | 1 (2.1) |
| General disorders and administration site conditions | 1 (8.3) | 1 (8.3) | | 0 (0.0) | | 0 (0.0) | | 3 (16.7) | | 3 (16.7) | | 0 (0.0) | | 0 (0.0) | 2 (11.1) | 1 (5.6) | | 1 (5.6) | | 0 (0.0) | | 6 (12.5) |
| Fatigue | 0 (0.0) | 0 (0.0) | | 0 (0.0) | | 0 (0.0) | | 1 (5.6) | | 1 (5.6) | | 0 (0.0) | | 0 (0.0) | 1 (5.6) | 0 (0.0) | | 1 (5.6) | | 0 (0.0) | | 2 (4.2) |
| Axillary pain | 0 (0.0) | 0 (0.0) | | 0 (0.0) | | 0 (0.0) | | 1 (5.6) | | 1 (5.6) | | 0 (0.0) | | 0 (0.0) | 0 (0.0) | 0 (0.0) | | 0 (0.0) | | 0 (0.0) | | 1 (2.1) |
| Feeling hot | 1 (8.3) | 1 (8.3) | | 0 (0.0) | | 0 (0.0) | | 0 (0.0) | | 0 (0.0) | | 0 (0.0) | | 0 (0.0) | 0 (0.0) | 0 (0.0) | | 0 (0.0) | | 0 (0.0) | | 1 (2.1) |

Table S5 continued, 2 of 5

|  | Placebo (N=12) n (%) | | | | 20 µg (N=18) n (%) | | | | 100 µg (N=18) n (%) | | | | Overall (N=48) n (%) |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| MedDRA SOC/PT | Any | Gr 1 | Gr 2 | Gr 3 | Any | Gr 1 | Gr 2 | Gr 3 | Any | Gr 1 | Gr 2 | Gr 3 | Any |
| Hangover | 0 (0.0) | 0 (0.0) | 0 (0.0) | 0 (0.0) | 1 (5.6) | 1 (5.6) | 0 (0.0) | 0 (0.0) | 0 (0.0) | 0 (0.0) | 0 (0.0) | 0 (0.0) | 1 (2.1) |
| Non-cardiac chest pain | 0 (0.0) | 0 (0.0) | 0 (0.0) | 0 (0.0) | 0 (0.0) | 0 (0.0) | 0 (0.0) | 0 (0.0) | 1 (5.6) | 1 (5.6) | 0 (0.0) | 0 (0.0) | 1 (2.1) |
| Injury, poisoning and procedural complications | 1 (8.3) | 1 (8.3) | 0 (0.0) | 0 (0.0) | 0 (0.0) | 0 (0.0) | 0 (0.0) | 0 (0.0) | 3 (16.7) | 2 (11.1) | 1 (5.6) | 0 (0.0) | 4 (8.3) |
| Muscle strain | 1 (8.3) | 1 (8.3) | 0 (0.0) | 0 (0.0) | 0 (0.0) | 0 (0.0) | 0 (0.0) | 0 (0.0) | 0 (0.0) | 0 (0.0) | 0 (0.0) | 0 (0.0) | 1 (2.1) |
| Animal bite | 0 (0.0) | 0 (0.0) | 0 (0.0) | 0 (0.0) | 0 (0.0) | 0 (0.0) | 0 (0.0) | 0 (0.0) | 1 (5.6) | 1 (5.6) | 0 (0.0) | 0 (0.0) | 1 (2.1) |
| Ear injury | 0 (0.0) | 0 (0.0) | 0 (0.0) | 0 (0.0) | 0 (0.0) | 0 (0.0) | 0 (0.0) | 0 (0.0) | 1 (5.6) | 1 (5.6) | 0 (0.0) | 0 (0.0) | 1 (2.1) |
| Foot fracture | 0 (0.0) | 0 (0.0) | 0 (0.0) | 0 (0.0) | 0 (0.0) | 0 (0.0) | 0 (0.0) | 0 (0.0) | 1 (5.6) | 0 (0.0) | 1 (5.6) | 0 (0.0) | 1 (2.1) |
| Respiratory, thoracic and mediastinal disorders | 1 (8.3) | 1 (8.3) | 0 (0.0) | 0 (0.0) | 2 (11.1) | 1 (5.6) | 1 (5.6) | 0 (0.0) | 1 (5.6) | 1 (5.6) | 0 (0.0) | 0 (0.0) | 4 (8.3) |
| Oropharyngeal pain | 1 (8.3) | 1 (8.3) | 0 (0.0) | 0 (0.0) | 1 (5.6) | 1 (5.6) | 0 (0.0) | 0 (0.0) | 1 (5.6) | 1 (5.6) | 0 (0.0) | 0 (0.0) | 3 (6.3) |
| Nasal congestion | 0 (0.0) | 0 (0.0) | 0 (0.0) | 0 (0.0) | 1 (5.6) | 0 (0.0) | 1 (5.6) | 0 (0.0) | 0 (0.0) | 0 (0.0) | 0 (0.0) | 0 (0.0) | 1 (2.1) |
| Blood and lymphatic system disorders | 0 (0.0) | 0 (0.0) | 0 (0.0) | 0 (0.0) | 0 (0.0) | 0 (0.0) | 0 (0.0) | 0 (0.0) | 3 (16.7) | 3 (16.7) | 0 (0.0) | 0 (0.0) | 3 (6.3) |
| Anaemia | 0 (0.0) | 0 (0.0) | 0 (0.0) | 0 (0.0) | 0 (0.0) | 0 (0.0) | 0 (0.0) | 0 (0.0) | 2 (11.1) | 2 (11.1) | 0 (0.0) | 0 (0.0) | 2 (4.2) |
| Lymphadenopathy | 0 (0.0) | 0 (0.0) | 0 (0.0) | 0 (0.0) | 0 (0.0) | 0 (0.0) | 0 (0.0) | 0 (0.0) | 1 (5.6) | 1 (5.6) | 0 (0.0) | 0 (0.0) | 1 (2.1) |
| Psychiatric disorders | 0 (0.0) | 0 (0.0) | 0 (0.0) | 0 (0.0) | 1 (5.6) | 0 (0.0) | 1 (5.6) | 0 (0.0) | 0 (0.0) | 0 (0.0) | 0 (0.0) | 0 (0.0) | 1 (2.1) |
| Anxiety | 0 (0.0) | 0 (0.0) | 0 (0.0) | 0 (0.0) | 1 (5.6) | 0 (0.0) | 1 (5.6) | 0 (0.0) | 0 (0.0) | 0 (0.0) | 0 (0.0) | 0 (0.0) | 1 (2.1) |
| Depression | 0 (0.0) | 0 (0.0) | 0 (0.0) | 0 (0.0) | 1 (5.6) | 0 (0.0) | 1 (5.6) | 0 (0.0) | 0 (0.0) | 0 (0.0) | 0 (0.0) | 0 (0.0) | 1 (2.1) |
| Reproductive system and breast disorders | 1 (8.3) | 0 (0.0) | 1 (8.3) | 0 (0.0) | 1 (5.6) | 1 (5.6) | 0 (0.0) | 0 (0.0) | 0 (0.0) | 0 (0.0) | 0 (0.0) | 0 (0.0) | 2 (4.2) |
| Intermenstrual bleeding | 0 (0.0) | 0 (0.0) | 0 (0.0) | 0 (0.0) | 1 (5.6) | 1 (5.6) | 0 (0.0) | 0 (0.0) | 0 (0.0) | 0 (0.0) | 0 (0.0) | 0 (0.0) | 1 (2.1) |
| Uterine spasm | 1 (8.3) | 0 (0.0) | 1 (8.3) | 0 (0.0) | 0 (0.0) | 0 (0.0) | 0 (0.0) | 0 (0.0) | 0 (0.0) | 0 (0.0) | 0 (0.0) | 0 (0.0) | 1 (2.1) |
| Vascular disorders | 0 (0.0) | 0 (0.0) | 0 (0.0) | 0 (0.0) | 1 (5.6) | 1 (5.6) | 0 (0.0) | 0 (0.0) | 1 (5.6) | 1 (5.6) | 0 (0.0) | 0 (0.0) | 2 (4.2) |
| Haematoma | 0 (0.0) | 0 (0.0) | 0 (0.0) | 0 (0.0) | 1 (5.6) | 1 (5.6) | 0 (0.0) | 0 (0.0) | 0 (0.0) | 0 (0.0) | 0 (0.0) | 0 (0.0) | 1 (2.1) |
| Hypotension | 0 (0.0) | 0 (0.0) | 0 (0.0) | 0 (0.0) | 0 (0.0) | 0 (0.0) | 0 (0.0) | 0 (0.0) | 1 (5.6) | 1 (5.6) | 0 (0.0) | 0 (0.0) | 1 (2.1) |
| Metabolism and nutrition disorders | 1 (8.3) | 0 (0.0) | 1 (8.3) | 0 (0.0) | 0 (0.0) | 0 (0.0) | 0 (0.0) | 0 (0.0) | 0 (0.0) | 0 (0.0) | 0 (0.0) | 0 (0.0) | 1 (2.1) |
| Decreased appetite | 1 (8.3) | 0 (0.0) | 1 (8.3) | 0 (0.0) | 0 (0.0) | 0 (0.0) | 0 (0.0) | 0 (0.0) | 0 (0.0) | 0 (0.0) | 0 (0.0) | 0 (0.0) | 1 (2.1) |

*N = Total number of volunteers in the safety analysis population per group  
n = For the 'Any' columns, cells present the number of volunteers with at least one event (volunteers with >1 reported event are counted only once). For the by grade columns, cells present the number of volunteers with at least one event at the maximum reported severity (volunteers with >1 reported event are counted only once and only at the maximum reported severity).  
% = Percentage of volunteers in each category, i.e., 100 x n/N  
Gr = Grade Maximum reported severity over all events was grade 3.*   
*MedDRA = Medical Dictionary for Regulatory Activities*

*SOC = System Organ Class*

*PT = Preferred Terms*

*MedDRA SOCs and PTs within SOCs are presented by descending overall frequency of volunteers with an event.  
Unsolicited AEs are presented through 28 days after the final vaccination.*